Prostaglandin E 2 (PGE 2 ) is an abundant lipid inflammatory mediator with potent but incompletely understood anti-inflammatory actions in the lung. Deficient PGE 2 generation in the lung predisposes to airway hyperresponsiveness and aspirin intolerance in asthmatic individuals. PGE 2 -deficient ptges −/− mice develop exaggerated pulmonary eosinophilia and pulmonary arteriolar smoothmuscle hyperplasia compared with PGE 2 -sufficient controls when challenged intranasally with a house dust mite extract. We now demonstrate that both pulmonary eosinophilia and vascular remodeling in the setting of PGE 2 deficiency depend on thromboxane A 2 and signaling through the T prostanoid (TP) receptor. Deletion of TP receptors from ptges −/− mice reduces inflammation, vascular remodeling, cytokine generation, and airway reactivity to wild-type levels, with contributions from TP receptors localized to both hematopoietic cells and tissue. TP receptor signaling ex vivo is controlled heterologously by E prostanoid (EP) 1 and EP 2 receptor-dependent signaling pathways coupling to protein kinases C and A, respectively. TP-dependent up-regulation of intracellular adhesion molecule-1 expression is essential for the effects of PGE 2 deficiency. Thus, PGE 2 controls the strength of TP receptor signaling as a major bronchoprotective mechanism, carrying implications for the pathobiology and therapy of asthma.
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cyclooxygenase | EP receptors P rostaglandins (PGs) derive from the metabolism of arachidonic acid by cyclooxygenase (COX)-1 and COX-2 (1). COX-derived PGH 2 is converted to one of five PGs [PGD 2 , PGE 2 , PGF 2 α, PGI 2 , or thromboxane A 2 (TXA 2 )] by distinct terminal synthases. Specific G protein-coupled receptors (2) mediate the effects of PGs in vivo, including roles in regulation of vascular tone, hemostasis, hematopoiesis, epithelial cell turnover, cancer, and inflammation (1) . Although COX inhibitors control inflammatory pain (3) and may prevent vascular disease and certain cancers (1), these reagents can also interfere with the production of PGs needed for homeostatic functions and cause unwanted side effects (1, 4) . PGE 2 is one of the most functionally versatile PGs. Three terminal synthases can convert PGH 2 to PGE 2 (5) (6) (7) . Of these, microsomal PGE 2 synthase (mPGES)-1 is the dominant enzyme responsible for converting COX-2-derived PGH 2 to PGE 2 during inflammation (8) . Four E prostanoid (EP) receptors (9) mediate the effects of PGE 2 . PGE 2 is pathogenetic in models of autoimmune diseases (10) and inflammatory arthritis (8) , but is bronchoprotective (11) and anti-inflammatory (12, 13) in certain models of allergic lung disease. In patients with atopic asthma, inhalation of PGE 2 blocks bronchoconstriction in response to challenge with inhaled specific allergen (14) and attenuates the recruitment of eosinophils and basophils to the airway. Reduced PGE 2 levels in the setting of sputum eosinophilia correlate with airway hyperresponsiveness (AHR) (15) , a cardinal feature of asthma. Aspirin-exacerbated respiratory disease (AERD), a severe variant of asthma, is associated with deficient COX-2-derived PGE 2 production (16) (17) (18) (19) and reduced expression of the EP 2 receptor (20, 21) , as well as marked tissue eosinophilia and bronchoconstrictive responses to the administration of nonselective COX inhibitors. These findings suggest potential therapeutic applications of PGE 2 in asthma and AERD if the mechanisms responsible for the homeostatic functions of PGE 2 in asthma can be fully defined.
An extract (Df) of the house dust mite Dermatophagoides farinae contains clinically relevant protease allergens, as well as adjuvants (glycans, endotoxin) that elicit sensitization through the airway mucosa, resulting in eosinophilic airway inflammation and a mixed T helper (Th)2, Th1, and Th17 pulmonary immune response (22) . PGE 2 -deficient mice with a targeted deletion in the gene encoding mPGES-1 (ptges −/− mice) develop increased bronchovascular eosinophilia compared with WT C57BL/6 controls when challenged intranasally with a low dose (3 μg) of Df (12), revealing a bronchoprotective effect of endogenous PGE 2 . This effect is restored by administration of agonists of the EP 1 , EP 2 , and EP 3 receptors. Df-challenged ptges −/− mice also develop extensive remodeling of the small-to medium-sized pulmonary arterioles (12) , a feature observed with sustained pulmonary Th2 responses in WT mice induced by inhaled allergens (23) . TXA 2 , a platelet-derived PG, activates endothelial-dependent leukocyte recruitment (24) , causes constriction and proliferation of pulmonary vascular smooth muscle (25, 26) , and amplifies airway reactivity to methacholine (MCh) in humans (27) . Because of its prominent pulmonary vascular and airway effects, we speculated that TXA 2 might mediate the pathologic effects of PGE 2 deficiency in the lung. We now demonstrate that virtually all functional and immunologic perturbations resulting from PGE 2 deficiency in Df-treated mice are prevented by the deletion of tpr encoding the T prostanoid (TP)α and TPβ receptors for TXA 2 . PGE 2 mediates bronchoprotection in part by controlling TXA 2 effector pathways, suggesting that pharmacologic blockade of TP receptors may prove helpful for the treatment of asthma variants in which local PGE 2 -mediated homeostasis is deficient. Because the vascular remodeling observed in Df-challenged ptges −/− mice suggested a potential contribution from TP receptors, we eliminated TP receptors in ptges −/− mice by mating them with tpr −/− C57BL/6 mice (28). As expected, the intranasal administration of Df (3 μg) elicited mild inflammation in WT C57BL/6 mice, and severe inflammation in ptges −/− mice (12) . Ptges −/− mice demonstrated higher total bronchoalveolar lavage (BAL) fluid cell counts, eosinophils, macrophages, lymphocytes, and neutrophils relative to WT controls (Fig. 1A) . Df-challenged ptges −/− mice had slightly more Periodic acid-Schiff (PAS)-staining goblet cells and cellular infiltration of their bronchovascular structures than did the WT controls (Fig. 1B , Top, as shown in Fig. 1C) . Deletion of tpr from the ptges −/− mice reduced all of these features to levels indistinguishable from or below those of WT controls (Fig. 1) . Findings in WT controls did not differ from those in the tpr −/− single KO mice ( Fig. 1) , although single KO mice showed reduced eosinophilic inflammation in experiments where the dose of Df was increased to 10 μg (Fig. S1 ).
Results and Discussion
Pulmonary arteriolar remodeling is not a feature of asthma in humans, but develops in sensitized WT mice treated with longterm or high-dose allergen (23, 29) . In our previous study (12) , ptges −/− mice developed significant increases in the numbers of α-smooth muscle actin (α-SMA) + cells and the thickness of the α-SMA + cell layer in lung sections at doses of dust mite allergen ∼10-fold lower than those used to elicit this response in WT mice in other reports (29) . Administration of selective EP 1 , EP 2 (especially), and EP 3 agonists protected ptges −/− mice from remodeling (12) . In the present study, the Df-induced vasculopathy in the ptges −/− mice was completely eliminated by the introduction of the tpr −/− allele (Fig. 2) . Treatment of the ptges −/− mice with intraperitoneal injections of the selective TP receptor antagonist SQ 29,548 each day (2 mg/kg of body weight) during the period of Df challenge reduced total BAL cell and eosinophil counts (Fig.  S2A ), bronchovascular inflammation, goblet cell metaplasia, and vascular remodeling (Fig. S2B ). These data strongly indicate that TP receptors are dominant effectors of pulmonary inflammation and its pathophysiologic consequences when PGE 2 is depleted.
Deletion of TP Receptors Eliminates the Increment in Airway
Reactivity Observed in Df-Challenged PGE 2 -Deficient Mice. AHR to MCh is a feature of asthma that is potentiated after allergen challenge of atopic humans. Although inhaled PGE 2 blocks allergen-induced potentiation of AHR (14), inhaled TXA 2 causes bronchoconstriction and potentiates AHR (27) . Although exogenously administered PGE 2 and TXA 2 , respectively, dampen and potentiate airway reactivity to MCh in mice (11, 30) , the roles of endogenous PGs in controlling allergen-induced AHR are less clear. Indeed, a recent study reported that ptges −/− mice showed reduced MCh reactivity compared with WT controls in a model of pulmonary disease where mice were immunized systemically to ovalbumin (31) . In contrast to that study, Df-challenged ptges −/− mice displayed greater AHR than did Df-challenged WT mice over the entire range of MCh doses (6.25-100 mg/mL). Deletion of the tpr allele from the ptges −/− mice restored MCh reactivity following Df challenge to WT levels (Fig. 3) . Thus, endogenous PGE 2 is strongly bronchoprotective against AHR in our model, and does so at least in part by suppressing the pathogenetic contribution from TP receptors. Tpr deletion also slightly increased basal reactivity to the highest doses of MCh in naive, PGE 2 -sufficient mice (Fig. 3) .
Deletion of TP Receptor Signaling Attenuates Th2-Type Recall
Responses to Df. Allergen-induced eosinophilic inflammation, pulmonary vascular remodeling, and AHR in mice are all characteristic signatures of Th2-type cytokines (23, 32) . Df elicits a mixed Th1, Th2, and Th17-type pulmonary immune response in mice based on cytokine profiles of restimulated lung-draining parabronchial lymph node (PLN) cells. Because both PGE 2 and TXA 2 can exert complex effects on T cells depending on the model studied (33, 34), we measured cytokines generated by Df-restimulated PLN cells from each strain. The cells from Df-treated ptges −/− mice generated more IL-4, IL-5, IL-13, and IL-17A than did the cells from WT animals, but produced less IFN-γ (Fig. S3 ). This finding is consistent with previous reports that PGE 2 promotes IFN-γ production in a Th1-dependent model of contact hypersensitivity (10) . Because IFN-γ counteracts Th2 cell development, the lower level of IFN-γ generated by the ptges −/− PLN cells could amplify Th2 cytokine production occurring in our model. Deletion of the tpr allele reduced the levels of Th2 cytokines in both PGE 2 -deficient and -sufficient genetic backgrounds (Fig. S3) , and also reduced the levels of serum IgE and specific IgG1 (Fig. S4) . Treatment with SQ 29,548 also reduced Th2 cytokine generation, although this was significant only for the PLNs from the ptges −/− mice (Fig. S2C) . Thus, the pathologic and physiologic features of our model that are enhanced and abrogated by the absences of mPGES-1 and TP receptors could in part reflect the influences of PGE 2 and TXA 2 , respectively, on cytokine production by T cells. The reduced levels of allergen-specific IgE and IgG1 could explain some of the protective effects of TP receptor deletion.
Absence of PGE 2 Does Not Increase TP Receptor-Dependent Pathology by Enhancing TXA 2 Formation. COX-2 and mPGES-1 ensure increased PGE 2 production with inflammation (35) . Deletion of mPGES-1 can therefore alter the synthesis of other PGs through shunting of the COX-2-derived PGH 2 to other terminal synthases (36) . We monitored the generation of all PGs by the cells of enzymatically dispersed lung cells from all strains. Df challenge induced a marked (∼threefold) increase in PGE 2 generation by the lung cells of WT mice that were incubated ex vivo with arachidonic acid (50 μM), and increased the productions of PGF 2 α, PGI 2 , PGD 2 , and TXA 2 more modestly (Fig.  S5) . Consistent with our previous study (12) , the deletion of ptges impaired the conversion of arachidonic acid to PGE 2 by the lung cells from Df-challenged mice, without altering conversion to other PGs (Fig. S5) , but the deletion of TP receptors had no effect.
Because TXA 2 synthesis was not enhanced in the absence of mPGES-1, we suspected that the amplification of TP receptordependent contributions in this strain reflected deficient crossregulation of TP receptor signaling by EP receptors. TP receptors in the lung are constitutively serine-phosphorylated by other receptors that maintain cAMP-dependent PKA activity, limiting the strength of TP receptor signaling (37, 38) . TP receptors can also be phosphorylated and desensitized by PKC (38) . As noted above, EP 1 , EP 2 , and EP 3 agonists all protect ptges −/− mice from vascular remodeling (12) , and the EP 2 agonist also blocked bronchovascular inflammation and BAL fluid eosinophilia. Narumiya and colleagues showed a homeostatic role for EP 3 receptor signaling in a model of ovalbumin-induced airway disease (39). EP 2 and EP 4 receptors activate PKA (9), whereas EP 1 and EP 3 receptors can activate PKC (40, 41). We studied crossregulation ex vivo in platelets and human umbilical vein endothelial cells (HUVEC), both of which express TP (42, 43) and EP receptors (42) . The TP receptor-selective agonist U-46619 dosedependently induced CD62P expression by platelets (Fig. 4 A  and B) . The platelets from tpr −/− mice showed no response to U-46619 (Fig. 5B) . Pretreatment with an EP 1 receptor agonist (DI-004) suppressed TP-dependent induction of CD62P (Fig. 4C) , whereas agonists of EP 2 (AE1-259-01), EP 3 (AE-248), and EP 4 receptors showed no effect below 10 μM. The effect of the EP 1 agonist was reversed by treatment of the samples with the PKC inhibitors Go6976 and Calphostin C (Fig. 4D) . U-46619 induced the expression of intercellular adhesion molecule (ICAM)-1 by HUVEC (Fig. 4 E and F) . This induction was blocked by pretreatment with AE1-259-01 (0.1-10 μM) or the stable PGE 2 analog 16, 16-diPGE 2 (10 μM), but not with the other EP receptor selective agonists (Fig. 4 E and F) . The EP 2 receptordependent blockade of ICAM-1 induction was reversed by the PKA inhibitor H89 (Fig. 4 E and F) but not by the PKC inhibitor Go6976 (Fig. 4E) . Thus, TP receptor signaling on both hematopoietic and nonhematopoietic cells can be desensitized by EP 1 and EP 2 receptors through respective PKC-and PKA-dependent signaling pathways, consistent with the hypothesis that PGE 2 controls allergic pulmonary inflammation by maintaining heterologous desensitization of TP receptors.
TP Receptors Expressed by both Resident and Hematopoietic Cells
Contribute to the Enhanced Pulmonary Response to Allergen in the Setting of PGE 2 Deficiency. To determine the extent to which TP receptors on hematopoietic cells and on resident tissue cells were important in our model, we generated chimeric ptges −/− mice lacking TP receptors on nonbone marrow-derived cells by transferring ptges −/− bone marrow into lethally irradiated double-KO mice. We also generated chimeric ptges −/− mice lacking TP receptors on bone marrow-derived cells by transferring double-KO bone marrow into irradiated ptges −/− mice. After 10 wk, the chimeric mice were challenged with either Df or saline. Control ptges −/− mice that were reconstituted with ptges −/− bone marrow developed Df-induced increases in total BAL fluid cell numbers, eosinophils, bronchovascular cellular infiltrates, and goblet cell metaplasia in response to Df. In contrast, double-KO mice reconstituted with double-KO bone marrow showed little response to Df challenge on all parameters (Fig. S6 A-D) . Mice lacking TP receptors only on the hematopoietic compartment and mice lacking TP receptors only on the tissue compartment demonstrated Df-induced BAL fluid eosinophilia, bronchovascular inflammation, and PLN cytokine production that were intermediate between the ptges −/− and double-KO mice reconstituted with marrow from their corresponding respective identical littermates (Fig. S6) . Peripheral blood cell counts were similar among the various groups (WBC counts ranging from 2.15 ± 0.43 to 3.07 ± 1.01 × 10 3 cells/μL, mean ± SD) and no different from the nonirradiated age-matched WT mice (2.77 ± 0.55 × 10 3 cells/μL). Thus, the functions of TP receptors on hematopoietic cells and nonhematopoietic cells are synergistic in this model, potentially reflecting the contributions of TP receptors to platelet-dependent priming of granulocyte adhesiveness (24, 44, 45) and enhancement of endothelial adhesion molecule expression (24) , respectively. Both of these contributions may be held in check by PGE 2 .
PGE 2 Deficiency Augments ICAM-1-Dependent Pulmonary Leukocyte
Recruitment in Vivo. We next sought to directly determine whether TP receptors regulated leukocyte recruitment to the lung in the setting of PGE 2 deficiency by controlling the expression of ICAM-1. Double immunofluorescent staining with anti-ICAM-1 and anti-α-SMA (to identify the bronchovascular structures) revealed ICAM-1 staining in the WT and ptges −/− strains that tended to be more intense after challenges with Df (Fig. 5A , green fluorescence). Confocal images of lung double-stained with Abs against ICAM-1 and platelet endothelial adhesion molecule-1 (PECAM-1) revealed strong ICAM-1 signals on the PECAM-1 − alveolar epithelium, with additional colocalization to PECAM-1 + endothelial cells (Fig. 5B) . Df treatment strongly up-regulated ICAM-1 protein expression in the lungs of WT mice, and more strongly in the ptges −/− mice (Fig. 5C ). Remarkably, Df treatment failed to up-regulate ICAM-1 protein in the lungs of tpr −/− and double-KO mice (Fig. 5C ). To determine whether the TP receptor-driven ICAM-1 expression observed in the ptges −/− mice accounted for the pathologic features observed in this strain, we treated WT and ptges −/− mice with intraperitoneal injections of blocking anti-ICAM-1 Abs or isotype controls during the period of Df challenge. ICAM-1 blockade markedly decreased the numbers of total cells and eosinophils in the BAL fluids from the ptges −/− mice and in the WT controls (Fig. S7A) , and also reduced the bronchovascular inflammation, goblet cell metaplasia, and arteriolar remodeling (Fig. S7B, as shown in Fig. S7C ). Anti-ICAM-1 treatment reduced the numbers of cells recovered from the PLNs of both strains of mice, and reduced the levels of IL-4, IL-5, and IL-13, but not IL-17A generated by the cells from both strains (Fig. S8) . Thus, EP and TP receptor signaling pathways respectively dampen and induce ICAM-1 expression in the lung, controlling susceptibility to the pathologic and physiologic changes resulting from Df. The lack of PGE 2 likely dysregulates the control of TP receptor-dependent ICAM-1 expression as a major phenotypic component of the ptges −/− strain. Our study suggests that the long recognized homeostatic function of PGE 2 in allergic pulmonary inflammation (12) (13) (14) and airway reactivity (15, 46) involves cross-regulation of TP receptor function. EP receptors "fine-tune" the strength of signaling through TP receptors by activating PKA and PKC. Consequently, TP-dependent effects become magnified in the setting of inflammation if the capacity to up-regulate PGE 2 generation (or to signal through EP receptors) is impaired. Deficient PGE 2 may potentiate AHR in the setting of eosinophilic inflammation (15, 47) . Defective COX-2-dependent production of PGE 2 and deficient expression of EP 2 receptors have both been documented in AERD (19, 21, 48) , and might account for the marked eosinophilic airway inflammation and high basal levels of leukotriene E 4 typical of this syndrome. The lack of a contribution from COX-2 to the generation of homeostatic PGE 2 may explain the fact that COX-2-selective agonists are well-tolerated in AERD (49) . Because aspirin potently inhibits COX-1 but only weakly inhibits COX-2 (50), most asthmatic individuals likely tolerate aspirin because of the persistent bronchoprotection provided by "aspirin resistant" COX-2/mPGES-1-derived PGE 2 . Conversely, the inability to maintain COX-2/mPGES-1-derived PGE 2 when COX-1 is inhibited could explain the characteristic surge in cysteinyl leukotriene production and bronchoconstriction in response to challenges with low-dose (30-160 mg) aspirin in individuals with AERD. Basal COX-1-derived TXA 2 formation is unimpaired in AERD (45) . Subsequently, the interference with TXA 2 generation (51) could explain part of the apparently paradoxical therapeutic benefit of aspirin treatment in patients with AERD after they are clinically desensitized (52) . Existing orally active TP receptor agonists have shown moderate efficacy in reducing AHR or sputum eosinophilia in small controlled studies of individuals with asthma (53) (54) (55) . Such antagonists may have major efficacy as treatments for asthma in individuals stratified for lower levels of pulmonary PGE 2 production or deficient EP receptor signaling, such as those with AERD (21).
Methods
Mice. C57BL/6 ptges −/− mice were from Satoshi Uematsu (Osaka University, Osaka, Japan). C57BL/6 tpr −/− mice were provided by Thomas Coffman (Duke University, Durham, NC). ptges −/− males were intercrossed with tpr −/− females to obtain double-KO (ptges/tpr −/− ) mice. The mice and the WT controls were housed at Charles River. All studies were conducted on 6-to 8-wk-old male mice and were approved by the Animal Care and Use Committee of the Dana-Farber Cancer Institute. Df challenges, cellular and standard histologic analyses, restimulation of PLN cells, measurements of Abs, and GC-MS analyses were all performed as described previously (12, 56) .
Bone Marrow Transfer. Five-week-old mice were lethally irradiated with 1,200 rads (12 Gy) in two split doses, 4 h apart. Within 24 h of irradiation, 1 × 10 7 bone marrow cells were infused via the tail vein into sex-matched irradiated mice in 200 μL of PBS. For the first 8 wk after the injection of bone marrow cells, chimeric mice drank water supplemented with enrofloxacin (Baytril; Bayer Health Care). Ten weeks after the injection, mice were exposed to six doses of saline or Df and killed 24 h after the last challenge. Peripheral blood cell counts were performed before the beginning of treatment to ensure full engraftment.
ICAM-1 Blocking. Twenty-four hours before each Df challenge, mice were injected intraperitoneally with 50 μg of a neutralizing Ab against mouse ICAM-1 (clone YN1/1.7.4; Biolegend) or rat IgG2b-κ isotype control Ab (Biolegend). Mice were treated with 3 μg of Df twice weekly for 3 wk.
Statistical Analysis. Data are expressed as mean ± SD. Statistical analyses were performed using ANOVA. Differences were considered significant when P values were less than 0.05.
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